Ghalia Al Yazidi1,2, Luan T Tran1,2,3,4, Kether Guerrero1,2,3,4, Adeline Vanderver5,6, Raphael Schiffmann7, Nicole I Wolf8, Sylvain Chouinard9, Geneviève Bernard1,2,3,4. 1. Department of Neurology and Neurosurgery McGill University Montreal Canada. 2. Department of Pediatrics McGill University Montreal Canada. 3. Division of Medical Genetics, Department of Internal Medicine McGill University Health Center Montreal Canada. 4. Child Health and Human Development Program Research Institute of the McGill University Health Center Montreal Canada. 5. Department of Neurology, Perelman School of Medicine University of Pennsylvania Philadelphia PA USA. 6. Division of Neurology Children's Hospital of Philadelphia Philadelphia PA USA. 7. Institute of Metabolic Disease, Baylor Scott & White Research Institute Dallas TX USA. 8. Department of Child Neurology VU University Medical Center, and Amsterdam Neuroscience Amsterdam Netherlands. 9. Centre hospitalier universitaire Sainte-Justine Montréal Canada.
Abstract
OBJECTIVES: To identify the prevalence of dystonia in a RNA Polymerase III (POLR3)-related leukodystrophy patient cohort and to further characterize their dystonic features. BACKGROUND: POLR3-related leukodystrophy is a hypomyelinating leukodystrophy characterized by neurological and non-neurological features. Dystonia remains a challenging and under-recognized feature. METHODS: A retrospective chart review was performed in a cohort of 20 patients for whom videos of a standardized neurological examination were available. Patients were recruited at the Montreal Children's Hospital of the McGill University Health Center and the Myelin Disorders Bioregistry Project. Families were consented at the initial assessment and the following data was recorded: age and symptoms at clinical presentation, investigations, causal gene and mutation(s), type and severity of dystonia, and treatment response when needed. Standardized examination videos were reviewed by three independent reviewers and scored using the Global Dystonia Scale. RESULTS: 10 males and 10 females were included in this study; 12/20 had POLR3A mutations, while 8/20 had POLR3B mutations; 19/20 patients had documented dystonia, with 3/19 requiring therapy. There was a good response in two patients to a single agent, and a poor response in one patient to three agents; the majority had mild-to-moderate multifocal dystonia without a functional impact. CONCLUSIONS: Dystonia is a common, yet underdiagnosed, slowly progressive manifestation of POLR3-related leukodystrophy, and in most cases has limited-to-no functional impact. When treatment is needed, good response to typically used medication may occur. Further studies are needed to assess evolution of dystonia over time, patients' functional outcome, and response to therapy (when needed).
OBJECTIVES: To identify the prevalence of dystonia in a RNA Polymerase III (POLR3)-related leukodystrophy patient cohort and to further characterize their dystonic features. BACKGROUND: POLR3-related leukodystrophy is a hypomyelinating leukodystrophy characterized by neurological and non-neurological features. Dystonia remains a challenging and under-recognized feature. METHODS: A retrospective chart review was performed in a cohort of 20 patients for whom videos of a standardized neurological examination were available. Patients were recruited at the Montreal Children's Hospital of the McGill University Health Center and the Myelin Disorders Bioregistry Project. Families were consented at the initial assessment and the following data was recorded: age and symptoms at clinical presentation, investigations, causal gene and mutation(s), type and severity of dystonia, and treatment response when needed. Standardized examination videos were reviewed by three independent reviewers and scored using the Global Dystonia Scale. RESULTS: 10 males and 10 females were included in this study; 12/20 had POLR3A mutations, while 8/20 had POLR3B mutations; 19/20 patients had documented dystonia, with 3/19 requiring therapy. There was a good response in two patients to a single agent, and a poor response in one patient to three agents; the majority had mild-to-moderate multifocal dystonia without a functional impact. CONCLUSIONS: Dystonia is a common, yet underdiagnosed, slowly progressive manifestation of POLR3-related leukodystrophy, and in most cases has limited-to-no functional impact. When treatment is needed, good response to typically used medication may occur. Further studies are needed to assess evolution of dystonia over time, patients' functional outcome, and response to therapy (when needed).
Authors: N I Wolf; I Harting; E Boltshauser; G Wiegand; M J Koch; T Schmitt-Mechelke; E Martin; J Zschocke; B Uhlenberg; G F Hoffmann; L Weber; F Ebinger; D Rating Journal: Neurology Date: 2005-04-26 Impact factor: 9.910
Authors: M Timmons; M Tsokos; M Abu Asab; S B Seminara; G C Zirzow; C R Kaneski; J D Heiss; M S van der Knaap; M T Vanier; R Schiffmann; K Wong Journal: Neurology Date: 2006-12-12 Impact factor: 9.910
Authors: Salim Atrouni; Antoine Darazé; Jean Tamraz; Antoine Cassia; Catherine Caillaud; André Mégarbané Journal: Am J Med Genet A Date: 2003-04-01 Impact factor: 2.802
Authors: N I Wolf; I Harting; A M Innes; S Patzer; P Zeitler; A Schneider; A Wolff; K Baier; J Zschocke; F Ebinger; E Boltshauser; D Rating Journal: Neuropediatrics Date: 2007-04 Impact factor: 1.947
Authors: M Vázquez-López; Y Ruiz-Martín; P de Castro-Castro; C Garzo-Fernández; F Martín-del Valle; L Márquez-de la Plata Journal: Rev Neurol Date: 2008 Aug 16-31 Impact factor: 0.870
Authors: Inga Harting; Murtadha Al-Saady; Ingeborg Krägeloh-Mann; Annette Bley; Maja Hempel; Tatjana Bierhals; Stephanie Karch; Ute Moog; Geneviève Bernard; Richard Huntsman; Rosalina M L van Spaendonk; Maaike Vreeburg; Agustí Rodríguez-Palmero; Aurora Pujol; Marjo S van der Knaap; Petra J W Pouwels; Nicole I Wolf Journal: Neurogenetics Date: 2020-01-15 Impact factor: 2.660